Health-related quality of life in adults with low-grade gliomas: a systematic review.
Health-related quality-of-life
Low-grade glioma
Survivorship
Journal
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
accepted:
18
07
2022
pubmed:
6
8
2022
medline:
10
3
2023
entrez:
5
8
2022
Statut:
ppublish
Résumé
Low-grade glioma (LGG) patients may face health-related quality-of-life (HRQoL) impairments, due to the tumour, treatment and associated side-effects and prospects of progression. We systematically identified quantitative studies assessing HRQoL in adult LGG patients, for: aspects of HRQoL impacted; comparisons with non-cancer controls (NCC) and other groups; temporal trends; and factors associated with HRQoL. MEDLINE, CINAHL, Embase, PubMed, and PsycINFO were systematically searched from inception to 14th September 2021. Following independent screening of titles and abstracts and full-texts, population and study characteristics, and HRQoL findings were abstracted from eligible papers, and quality appraised. Narrative synthesis was conducted. Twenty-nine papers reporting 22 studies (cross-sectional, n = 13; longitudinal, n = 9) were identified. Papers were largely good quality, though many excluded patients with cognitive and communication impairments. Comparators included high-grade gliomas (HGG) (n = 7); NCCs (n = 6) and other patient groups (n = 3). Nineteen factors, primarily treatment (n = 8), were examined for association with HRQoL. There was substantial heterogeneity in HRQoL instruments used, factors and aspects of HRQoL assessed and measurement timepoints. HRQoL, primarily cognitive functioning and fatigue, in adult LGG patients is poor, and worse than in NCCs, though better than in HGG patients. Over time, HRQoL remained low, but stable. Epilepsy/seizure burden was most consistently associated with worse HRQoL. LGG patients experience wide-ranging HRQoL impairments. HRQoL in those with cognitive and communication impairments requires further investigation. These findings may help clinicians recognise current supportive care needs and inform types and timings of support needed, as well as inform future interventions.
Identifiants
pubmed: 35931881
doi: 10.1007/s11136-022-03207-x
pii: 10.1007/s11136-022-03207-x
pmc: PMC9992080
doi:
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
625-651Subventions
Organisme : Brain Tumour Charity
ID : GN-000435
Informations de copyright
© 2022. The Author(s).
Références
World Neurosurg. 2017 Jul;103:799-808.e9
pubmed: 28411105
Top Spinal Cord Inj Rehabil. 2014 Summer;20(3):167-80
pubmed: 25484563
J Clin Neurosci. 2014 Aug;21(8):1304-9
pubmed: 24798909
Support Care Cancer. 2006 Dec;14(12):1205-12
pubmed: 16710652
J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):373-7
pubmed: 11861699
Psychooncology. 2017 Feb;26(2):149-160
pubmed: 26918648
Support Care Cancer. 2012 Aug;20(8):1859-68
pubmed: 21979904
Oncologist. 2002;7(2):120-5
pubmed: 11961195
J Clin Oncol. 2007 Dec 20;25(36):5723-30
pubmed: 18089866
Front Neurol. 2019 Mar 15;10:212
pubmed: 30930834
Semin Oncol Nurs. 2018 Dec;34(5):472-485
pubmed: 30409554
Front Oncol. 2021 May 20;11:662039
pubmed: 34094955
J Neurooncol. 2011 May;103(1):129-36
pubmed: 20820874
J Clin Oncol. 2011 Nov 20;29(33):4430-5
pubmed: 22010018
J Clin Neurosci. 2021 Jun;88:259-267
pubmed: 33992194
Eur J Cancer. 1998 Nov;34(12):1902-9
pubmed: 10023313
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Neurooncol. 2007 Jan;81(2):175-84
pubmed: 16850104
J Neurooncol. 2009 Dec;95(3):413-419
pubmed: 19548070
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Jpn J Clin Oncol. 2015 Oct;45(10):906-13
pubmed: 26232448
PLoS One. 2012;7(12):e51450
pubmed: 23251537
Trials. 2015 Nov 03;16:495
pubmed: 26530985
Psychooncology. 2005 Sep;14(9):728-37
pubmed: 15669016
Ann Neurol. 2003 Oct;54(4):514-20
pubmed: 14520665
J Clin Oncol. 2015 Mar 20;33(9):1023-9
pubmed: 25667287
Brain Inj. 2001 Oct;15(10):843-56
pubmed: 11595081
Qual Life Res. 2017 Apr;26(4):869-880
pubmed: 27744512
World Neurosurg. 2018 Mar;111:e24-e31
pubmed: 29191529
Indian J Cancer. 2015 Oct-Dec;52(4):580-5
pubmed: 26960484
J Neurooncol. 2008 Feb;86(3):321-7
pubmed: 17926007
Neuro Oncol. 2021 Aug 2;23(8):1327-1336
pubmed: 33598685
CA Cancer J Clin. 2021 Sep;71(5):381-406
pubmed: 34427324
Neurooncol Pract. 2014 Jun;1(2):40-46
pubmed: 26034615
Psychooncology. 2013 Oct;22(10):2200-5
pubmed: 23508923
Oncology (Williston Park). 2017 Sep 15;31(9):680-2, 684-5
pubmed: 29071695
J Neurooncol. 2013 Feb;111(3):355-66
pubmed: 23292152
Clin Psychol Rev. 2019 Jul;71:27-38
pubmed: 31078056
Neuro Oncol. 2009 Jun;11(3):330-9
pubmed: 19001097
Eur J Oncol Nurs. 2020 Oct;48:101830
pubmed: 32971413
Psychol Health Med. 2019 Jul;24(6):643-653
pubmed: 30526021
World Neurosurg. 2018 Sep;117:e465-e474
pubmed: 29920391
Int J Speech Lang Pathol. 2014 Feb;16(1):82-94
pubmed: 24160320
Neurology. 2001 Mar 13;56(5):618-23
pubmed: 11245713
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
BMC Cancer. 2010 Jun 18;10:305
pubmed: 20565883
Eur Arch Psychiatry Clin Neurosci. 2006 Dec;256(8):516-21
pubmed: 16960653
Jpn J Clin Oncol. 2020 Sep 5;50(9):990-998
pubmed: 32484212
Acta Oncol. 2004;43(2):153-60
pubmed: 15163163
J Neurooncol. 2019 Apr;142(2):385-392
pubmed: 30706175
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Rehabil Med. 2013 May;45(5):434-45
pubmed: 23584801
Neurosurg Focus. 2015 Jan;38(1):E6
pubmed: 25552286
Neuro Oncol. 2016 Nov;18(11):1475-1486
pubmed: 27194147
J Neurol Neurosurg Psychiatry. 2007 Oct;78(10):1072-5
pubmed: 17259351
J Neurol. 2014 May;261(5):894-904
pubmed: 24590402
Front Psychol. 2019 Feb 19;10:330
pubmed: 30873074
Eur J Cancer. 2010 Apr;46(6):1033-40
pubmed: 20181476
CNS Oncol. 2014 Jan;3(1):37-47
pubmed: 25054899